Microbot Medical – Winner Spotlight: Innovative Start-up, Surgical Robotics Industry Awards 2026

Welcome to our Winner Spotlight Interview with Harel Gadot, CEO, President & Chairman, Microbot Medical, and winner of the Innovative Start-up category at the Surgical Robotics Industry Awards 2026!

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency, and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

The interview covers:

00:00 – Intro

00:41 – Congratulations on winning the Surgical Robotics Industry Award 2026. What does this recognition from the global surgical robotics community mean to you and the team at Microbot Medical?

01:24 – Can you give us an overview of Microbot Medical and your mission?

02:14 – What inspired Microbot Medical to focus specifically on endovascular procedures, and what challenges did you see in the field that robotics could help address?

03:29 – You received FDA clearance for the LIBERTY® System in September last year and have announced a steady stream of milestones since then. Can you talk us through some of the key developments and what they mean for the company?

05:16 – Can you explain the technology behind LIBERTY® and what differentiates it from other endovascular robotic solutions?

06:46 – Looking ahead, what’s next for Microbot Medical as you continue expanding the adoption of LIBERTY®, and what is your long-term vision for the company?

To learn more about Microbot Medical Inc., visit: https://www.microbotmedical.com/

To register your interest for the Surgical Robotics Industry Awards, visit: https://surgicalroboticsindustryaward…